Navigation Links
Accera, Inc. to Present at the 4th Annual BIO Investor Forum
Date:10/4/2007

BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, announced today that the company will be participating in the 4th Annual BIO Investor Forum next week at the Palace Hotel in San Francisco:

-- Dr. Lauren Costantini, Vice President of Clinical Development, will

contribute to the panel discussion, "Alzheimer's Disease - Novel

Mechanisms and Targets Renewing the Future of Patients" on Wednesday,

October 10 at 9:10 a.m. PDT.

-- Dr. Steve Orndorff, President and CEO, will present on Thursday,

October 11 at 11:00 a.m. PDT.

Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from the company's Phase IIb studies of its lead therapeutic product, Ketasyn(TM) (AC-1202) in Alzheimer's disease (AD) and age-associated memory impairment (AAMI). In both studies, Ketasyn was shown to significantly improve memory and cognition using a battery of neuropsychometric tests, including ADAS-Cog, the FDA's gold- standard efficacy measure for AD drugs. Ketasyn was also well tolerated in both indications, even when taken in addition to existing AD drugs, making it a promising candidate for a cotherapeutic approach to treating AD.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease and age-associated memory impairment (AAMI). A key element of Accera's strategy is to develop AC-1202 and other proprietary small molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. http://www.accerapharma.com

About Ketasyn(TM)

Brain imaging techniques performed on Alzheimer's patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn(TM) (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn demonstrates neuroprotective and disease modifying potential in a number other neurodegenerative diseases characterized by neuronal hypometabolism. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and selected orphan drug indications.

For information contact:

Meghan Feeks

Richard Lewis Communications, Inc.

212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):